The bizarre world of negative rate; FT article from G. Tett

FINANCE

The bizarre world of negative rates

August has been notable for yet another set of bizarre market signals. Last week the Bank of England cut rates from 0.5 per cent to a record low of 0.25 per cent and pledged to introduce a £70bn quantitative easing programme.

In the wake of that, yields on sovereign debt in the UK, Ireland and Spain have tumbled to record lows: the rate on benchmark 10-year gilts is now a mere 0.56 per cent while short-term notes have turned negative.

More startling still, the total global volume of sovereign and corporate bonds with negative nominal yields last week rose above $12.6tn, according to data assembled for the Financial Times by Tradeweb, the financial services group. That represents almost half of all western debt. By historical standards this is extraordinary — not least because investors continue to gobble up those notes, even though they will lose money on redemption.

If you want a further sign of how distorted the system is, take a look at another indicator that does not usually attract much attention because it is much harder to track: the attitude to cash of investors and treasurers.

In recent years it has often been assumed that one reason central banks cut rates is to force investors and companies to move funds from low-yielding assets, such as bonds or cash, into more productive investments that could produce better returns and growth.

But that economic theory is not playing out. A couple of weeks ago, for example, the US Association for Financial Professionals published a survey of corporate treasurers. This suggests that, far from becoming cash-averse, they are planning to increase rather than decrease their holdings of cash this summer. Indeed, they are more enthusiastic about cash than at any point since 2011.

A separate survey of investors from Bank of America Merrill Lynch echoes this point. In July the world’s biggest asset managers said they had 5.8 per cent of their assets in cash. The level has been rising this year and now stands at its highest point since November 2001, in the wake of the 9/11 terrorist attack on the World Trade Center. Remarkably, it even tops cash holdings during the post-Lehman panic in 2008.

What explains this state of affairs? One factor is that asset managers and investors are downbeat about the economy and pessimistic about the ability of central bankers — or anyone else — to raise inflation. The Association for Financial Professionals, for example, says US corporate treasurers fret about a “tepid domestic economy and continued sluggishness” of global growth. The Merrill Lynch survey shows that growth expectations are sinking.

But economic gloom cannot explain the entire tale. Neither the asset managers nor the treasurers are forecasting a full-blown recession, let alone the type of 1930s-style depression that bond prices might imply. On the contrary, in July “only” 17 per cent of asset managers predicted a recession at all.

So a more likely explanation is that the pattern reflects a more widespread, and profound, sense of uncertainty. AFP points to the fact that treasurers are worried about Brexit and political upheaval. The Merrill Lynch survey indicates that asset managers are very fearful about “geopolitical risk” and protectionism.

Ominously, investors are disoriented by the actions of central banks. One of the most fascinating details of the Merrill Lynch survey, for example, is that there has recently been a jump in the proportion of participants who expect that “at least one central bank” will introduce “helicopter money”— meaning it will hand out cash in a desperate bid to boost prices — in the next year. Indeed 39 per cent of respondents expect this. To put it another way, asset managers fear the policy landscape is about to become even weirder. That is yet another reason for fear.

It is possible to see a silver lining in this pattern. After all, as one leading American hedge fund told clients this week, the more investors stash their funds in ultra-low yielding assets, the more this creates a potential pile of unspent monetary “fuel” that could one day spark a recovery if that all-important ingredient of confidence returns.

Right now it is anybody’s guess what might light that flame of confidence and prompt investors to move their funds from low-yielding assets into something more productive. The one thing that is, sadly, clear is that the spark is unlikely to come from further central bank rate cuts alone. At least, not in a world that already has almost $13tn of negative-yielding bonds — and where the actions of central banks look less reassuring by the day.

Asset managers fear that the policy landscape is about to become weirder and more disorienting

New “Gene Hacking” Technology Ends All Disease…

This is a publication of one brand new trend about investment and our future from an American Think tank.

 

  • MIT Technology Review called it “the biggest biotech discovery of the century…”
  • The genius scientist behind this technology just founded a new startup…
  • And it could go public within the next 3 months…

Imagine a world without disease…Where Alzheimer’s, arthritis, cancer, diabetes and heart disease don’t exist. Where you never again have to visit a doctor, fear scarring surgery, or take a dozen pills every morning… Yet, you still easily live past 100. Amazingly, this wonderful world may only be a few years away.

That’s because, thanks to a new breakthrough technology, we are on the verge of eliminating virtually ALL disease… I know this sounds impossible… But wait until you see the proof before making up your mind, because this could help you, or someone you love.

In short, scientists have discovered how to “hack” our genes, and delete disease from our body. For example, the most common form of late-onset Alzheimer’s has been linked to a gene on chromosome 19.

With this new technology, scientists could simply find and delete this disease-causing gene. Just like that, Alzheimer’s is CURED… With a procedure as quick and easy as getting a flu-shot. Nobel Prize winning biologist, Dr. Craig Mello, said this about what I call “gene hacking”:

“It’s a real game changer. [When] I saw it working in my own lab, my jaw dropped.”

And the MIT Technology Review calls it: “the biggest biotech discovery of the century.”

It’s easy to see why Bill Gates, Google and others just invested $120 million in this new technology. And German pharmaceutical giant, Bayer, committed a whopping $353 million.

That’s because, this could disrupt the entire $3.2 trillion per year healthcare system…

The market for this is literally everybody worried about disease. But what’s exciting is, YOU still have a chance to get in on the ground floor…

That’s because, I believe this tiny company, founded by the inventor of this new technology, could IPO within the next 3 months.

I’ll tell you more about this company very shortly, including how to invest for the biggest potential gains… When this medical miracle goes mainstream, early investors could make a fortune… Companies with similar, but much more primitive technology, rewarded fast moving investors with gains of:

8,192%…

15,692%…

And 169,862%…

That’s enough to turn $10,000 into $16.9 million in a single trade.

The reason for these stellar gains is simple: there’s no bigger prize today than fighting disease and extending peoples’ lives. So when a biotech company discovers a true breakthrough, very lucky investors can grow their money 100-fold and more. But even that might not match the profit potential at hand…

That’s because, the new technology I’m going to tell you about is more affordable and more effective than anything else on the market. So the sky’s the limit with this… and the gains start as soon as the small company I’m going to tell you about goes public… I predict this could happen within the next 3 months. With that in mind, I urge you not to set this presentation aside to watch later. You need to know everything about this situation right now, so you can be positioned early to take the lion’s share of profits.

This is the story of the greatest medical discovery in human history…

Gives Sight to the Blind

It’s simple to see why “gene hacking” could soon be worth a massive fortune. Just listen to story of little Corey Hahn… When Corey was a baby, his mom would call him, but he’d just stare in her general direction. When he dropped a toy, he couldn’t find it again, even when it was right in front of him. And he could look directly at bright lights without hurting his eyes.

Corey was born virtually blind.

But today, he goes fishing with his father, rides his bike and even plays baseball…

That’s because, thanks to a breakthrough medical experiment, Corey’s sight has been restored. You see, Corey was born with a tiny genetic mutation that made him blind. As you probably know, genes are small strips of DNA that provide the blueprint for everything that happens in your body… The color of your hair to your heartbeat, it’s all determined by your genes. Your genes also tell your eyes to produce a protein called RPE65, and it’s crucial for sight.

But for Corey, that gene was malfunctioning and making him almost completely blind. What’s amazing is, doctors were able to insert a “fixed” version of that gene into Corey’s eyes…

Four days after the treatment, when Corey went to the zoo with his family, he told his mom, “the sun is hurting my eyes!” After spending the first 7 years of his life in darkness, Corey could finally see!

It was a miracle.

But Corey’s story doesn’t just provide hope for those who suffer from blindness… It’s proof that “gene hacking” could cure ALL disease, including Alzheimer’s, arthritis, diabetes and more.

Let me explain…

The End of ALL Disease?

Starting in 1990, the world’s largest collaborative biology project began: The Human Genome Project. Researchers spent 13 years identifying all of the approximately 25,000 genes in human DNA. One major discovery from this project was that, your genes play a key role in virtually all disease. The National Human Genome Research Institute reports on their website that:

“As we unlock the secrets of the human genome, we are learning that nearly all diseases have a genetic component.”

Consider Alzheimer’s…

Alzheimer’s is a degenerative brain disease that causes memory loss, confusion, and eventually death. It affects 5.1 million Americans, and will kill 85,000 people this year. But those numbers are expected to rise rapidly as the Baby Boomer generation gets older. One cause of late-onset Alzheimer’s is faulty genes on chromosome 19. But if you can fix these faulty genes, you could cure Alzheimer’s!

Or, heart disease…

Heart disease is the #1 killer in America, claiming 610,000 lives every year. To reduce your risk of heart disease, your doctor will tell you to follow a low-fat, low-salt diet and get plenty of exercise. But a recent study led by Harvard researchers has found it may not be that simple… Published in the renowned medical journal, The Lancet, the study found that genes could increase your risk of heart attack by 70%, regardless of factors like smoking and cholesterol levels.

Then there’s cancer…

By 2020, it’s expected we’ll spend $158 billion per year treating cancer in America. But current treatments could be missing the root cause of many cancers…

You see, it’s estimated that about 5 million Americans are at risk of cancer because of their genetics! If you could simply delete these cancer-causing genes from your body, then no more cancer! The list of diseases with a genetic component goes on and on… And the number of people genetic mutations affect is massive. So you can see why “gene hacking” has the potential to be so huge… Scientists could now have the power to “fix” faulty genes, quickly and easily, and simply wipe disease from your body.

Here’s how it works…

How “Gene Hacking” Could Wipe Disease from Your Body…

You’ve probably heard of gene therapy before. Scientists have been trying to modify DNA to treat disease since 1980. Up until now, current gene therapies have been risky, expensive and inefficient. But “gene hacking” technology could change everything…

Dr. Bettina Schmid at the German Center for Neurodegenerative Disease says it’s:

“Easy, cheap, everybody can do it, and it is efficient.”

Think of older gene therapies as the first mobile phones… clunky, inefficient and expensive. “Gene hacking” technology is like the modern smartphone… it’s vastly more powerful, much cheaper, and millions of people will use it.

In fact, “gene hacking” can be up to 100,000 times more efficient than older methods. It was discovered in 2012 by a brilliant French scientist who was researching bacteria…

Bacteria are among the oldest and most durable organisms on Earth. They can survive anywhere, in the world’s deepest ocean trench, on top of Mt. Everest, and even in outer space. The key to bacteria’s success is their high-tech immune system… When bacteria is infected, it can laser-target a virus’s DNA and simply delete it. Without DNA, the virus can’t replicate and spread. The infection is stopped.

The French scientist and her team discovered that this same mechanism could be used to cure disease in humans too.

For example, take a look at this strip of DNA…

Now imagine this section highlighted red is a gene mutation that causes colon cancer… Depending on the type of colon cancer, your odds for survival could be as low as 10% with current treatment options.

But with “gene hacking” technology, doctors could laser-target the mutated gene, cut it from your DNA, and insert a healthy copy. Just like that, colon cancer is cured! Better yet, “gene hacking” could eliminate the need for surgery, radiation and chemotherapy. You see, the procedure could be as simple, fast and safe as giving blood or getting a flu-shot. Compare this with today’s treatment options, and it’s easy to see why “gene hacking” could disrupt the entire $3.2 trillion healthcare system…

American Failure

In 1971, Richard Nixon declared “War on Cancer” with the National Cancer Act… Cancer would be cured by 1976. Of course, that never happened… This year alone, there will be 1.7 million new cancer cases, and 600,000 cancer deaths, in the US. The War on Cancer has been a failure. Even today’s best treatment options just aren’t good enough. In fact, current cancer “treatments” can be deadlier than the actual disease…

A study in Journal of the National Cancer Institute, found that, 41% of cancer patient deaths could be caused by the treatment!

Quote:

“…for 41% of these deaths, the cause was not attributed to cancer. The authors speculate that cancer treatment is the probable underlying cause for essentially all of these deaths.”

Yet millions still have to take the risk, because it’s the best we have…

Until now.

“Gene hacking” has the potential to be more effective, safer, and more efficient… And that means, some of the $100 billion spent on cancer treatment every year will start flowing to the tiny “gene hacking” company I’m going to tell you about… Currently valued at just $500 million, just a small slither of that revenue could increase this company’s size ten-fold or more…

But as you’ve seen, even that could be conservative…

A company with a truly breakthrough technology can see hyper growth comparable to Apple, Microsoft and Google… That’s why it’s key to get in before this goes mainstream. Again, we’re not talking about one therapy for one disease here…

“Gene hacking” could cure virtually ALL disease.

Think about that…

More than 225 million Americans take prescription drugs for some sort of ailment… It’s highly likely you, or someone you know, takes prescription drugs. In 2015, almost half a trillion dollars was spent on prescription drugs… that’s more than $2,000 per person. Some specialty drugs, such as a hepatitis C drug called Sovaldi, costs $1,000 per pill.

In fact, medical bills are the number one cause of bankruptcy in America. Beyond the huge cost, there are huge health risks too…

Many prescription drugs come with awful side-effects… Headaches, dizziness, blood clots… and even death!

In fact, prescription drugs kill more people in America than illegal drugs. A study, published on the FDA’s website, claims that at least 106,000 Americans die every year from prescription drugs…

Again, until now, Americans have been left with little choice… But “gene hacking” offers real hope… Instead of masking the symptoms of disease like pills do, “gene hacking” could actually cure the disease for good. That’s why there’s a mad scramble from investors and biotech companies to claim their share of the “gene hacking” market… One biologist from North Carolina State University, describes the scene like this:

‘‘You’ve got Fortune 50 companies fighting with start-ups fighting with universities,’’ he says.

‘That almost never happens. But with [gene hacking] the range of potential uses is so huge — everybody wants in.’’

In other words, this truly is a historic opportunity.

Backed by the Most Impressive Medical Minds in the World

Harvard, Stanford, Yale, University of Oxford, Johns Hopkins and many more top schools are dedicating teams to research “gene hacking”… Meanwhile, some of the world’s biggest pharmaceutical companies are trying to claim a share of what is bound to be a massive new market…

A $64 million funding round for the tiny company I’m going to tell you about included investments from:

Celgene, a 30-year-old company with a $77 billion market-cap…

And GlaxoSmithKline (GSK), Britain’s biggest pharmaceutical company. GSK was an early backer of another company you may have heard of, Amgen…

Since its IPO, Amgen is up 15,692%.

So, simply by following GSK’s lead then, you could have turned $10,000 into more than $1.5 million.

Could they do it again with the tiny “gene hacking” company I’m going to tell you about?

But that’s not all…

German pharmaceutical giant, Bayer, has inked a $335 million deal with this tiny company.

And Vertex Pharmaceuticals has committed to a partnership with them too – one that could be worth $2.6 billion!

Remember, this tiny company is currently valued at just $500 million…

But these in-the-know pharma giants think that’s about to change, and are vying for a share of the potential profits…

Of course, investors are seeing the opportunity too…

Its first major backer was Versant Ventures, with a $25m investment.

Then New Enterprise Associates (NEA) followed…

NEA is one of the world’s largest venture capital firm and has helped almost 200 companies IPO. That’s a stellar track-record…

So when they make a move, I pay close attention.

Remember, this company was founded by the co-inventor of this technology…

In 2015, Time magazine named her among the 100 most influential people of the year…

Her “gene-hacking” discovery also tipped to win the Nobel-prize.

In fact, one of the company’s advisers is already a Nobel prize winner…

Other advisers teach at the most prestigious schools in the country, including MIT, Harvard and Stanford.

In short, they’ve assembled a scientific dream team to dominate in this brand new area of medicine.

The writing is on the wall and it’s time for individual investors to get ready too…

But, because this is a private company (for now)…

The vast majority of “little guy” investors barely know anything about this…

That’s why I’ve compiled all my research on this company in a report called Venture Elite Hotlist

And I want to send you a copy FREE.

But first, let me explain why you can’t hesitate on this…

Why You Must Act Fast

As you know, buying as early as possible– before the crowd sends share price surging–gives you the best chance at the biggest gains…

But what you may not know, is that your window of opportunity to invest early is smaller than ever.

You see, the time it takes for companies to reach billion-dollar valuations is rapidly reducing…

Over the last few decades, it took on average about 20 years for the typical Fortune 500 company to reach a market capitalization of $1 billion.

But in 1998, Google was able to reach $1 billion in market cap in only eight years, which was considered fast at the time.

By 2004, Facebook had done it in six years.

By 2009, Uber had done it in four years.

In 2012, virtual-reality firm Oculus Rift did it in just over a year.

And as recently as 2014, a workplace productivity company called Slack pulled it off in eight months.

As you can see in this chart, it’s taking less and less time for companies to hit $1bn. And investors are reaping the benefits.

Facebook shareholders who bought at the IPO are now enjoying a 198% return on their investment.

And they’re the laggards. Tesla shareholders are up 930%.

Google shareholders… 1,266%.

Point is, you have to move fast, or risk missing out on the biggest gains.

The upshot is… it’s now possible to make 20-year gains in as little as 2-years, or perhaps even less.

That’s why it’s urgent you claim your FREE copy of Venture Elite Hotlist today, so you can do your due diligence on the small “gene hacking” company with time to spare.

So just how much could you expect to make investing in “gene hacking” technology?

How Much Could You Expect to Make?

This technology is so new, there’s really nothing to compare it to… so I honestly can’t say for sure how much you’ll make…

But using earlier breakthroughs in genetic science as a guide, the gains could be staggering…

Consider a company called Biogen…

In 1979 they successfully copied human proteins crucial to the immune system. This allowed them to create a breakthrough leukemia drug called INTRON A…

And the rest is history…

Today, the company has a market cap of $55 billion, and had you invested right when it IPO’d, you’d be sitting on an 8,192% gain.

Take a look…

That’s enough to turn a $10,000 investment into more than $819,000.

Gilead Sciences is another gene therapy company that was once unheard of…

Their drug called Atripla is essentially a “gene blocker”, it disables HIV’s ability to make copies of itself and spread.

It’s a much more limited technology than “gene hacking”…

Yet, if you were lucky enough to buy Gilead Sciences right after it IPO’d, you could have booked a 15,692% winner.

Just one trade, and you could have turned a small $10,000 stake into more than $1.5 million.

But amazingly, the next example trumps even that…

Another pioneer in gene-based therapies is a company called Amgen.

The company’s researchers spent two years searching 1.5 million DNA fragments for a gene called erythropoietin.

When they located it, they were able to copy it and create one of the most successful drugs in biotech history, EPOGEN.

Buying Amgen right after their IPO would have yielded as much as a staggering 169,862% gain.

That’s enough to turn $10,000 into $16.9 million in a single trade.

So, you see the amazing potential of gene therapy pioneers… one trade in any of them was enough to make you rich…

But, the small company I want to tell you about could do even better because it’s leading the next phase in gene therapy…

Their “gene hacking” technology is brand new and completely revolutionary…

It’s cheaper, easier and more efficient than anything else… and that’s the key to going mainstream.

It could easily match the 8,192% gain of Biogen, the 15,692% gain of Gilead, or even the 169,862% gain of Amgen.

I know that’s almost impossible to believe, and of course no investment – including this one – is guaranteed.

But remember…

These were all tiny, unheard of start-ups too. Now they’re biotech behemoths, and I expect the same to happen to our little “gene hacking” company.

So, how can you learn more about this investment right away?

As I mentioned, I’ve put all my research into a report called the Venture Elite Hotlist… and I want to send you a FREE copy.

But don’t judge the value of this report based on the fact I’m giving it away to a small group of folks reading today…

The research in this report was incredibly hard to compile…

You won’t find it anywhere else, not without spending a small fortune.

Have you ever wondered why you only hear about IPOs after the fact?

When the biggest gains have already been made?

That’s because a new law has made it much harder for you to learn about these exciting opportunities until the very last minute…

And by then, it could be too late for most folks.

Let me explain…

RESTRICTED!

4 years ago, it was easier to uncover this information. You’d hear about an IPO months in advance.

Now, it’s difficult. And most investors don’t have much time at all to prepare.

You see….

In 2012, Obama signed the JOBS act into law. You may have heard of it.

The purpose of the law was to give a “boost” to America’s small businesses.

Well, Congress snuck an odd clause in section 106 of the law, under the vague heading “other matters”…

Essentially, the clause allows private companies to make their initial filing to go public in complete secrecy.

A company covered by this act can apply for an IPO with the Federal Government… and no one knows about it. Not even many of the “pros.”

Some call this the “Secret IPO.” Or the “Dark Pipeline.”

According to the Wall Street Journal… about 850 companies have elected to go public this way—secretly.

When a company goes public this way… generally, the only time you and I hear about it is when they file a form with the U.S. Government called the “S-1/A.”

Once they fill out this form, you have anywhere from one month… to as little as a few days to investigate the business… and do all of your due diligence.

That’s bad news for most investors…

But good for you…

Because access to my Venture Elite Hotlist report gives you the inside scoop on these companies months in advance of their potential IPO…

It’s all thanks to a unique system I use to find companies that might IPO, months, even years before the event.

Here’s how it works…

How to Find “The Next Apple…”

My name is Jeff Brown and I’m the editor of a new research service called Exponential Tech Investor.

I have 25 years of experience as a tech industry insider, working at Juniper Networks, QUALCOMM and NXP Semiconductors.

So I’ve had a front row seat to some of the most significant tech breakthroughs of our time…

For example, my former employer, QUALCOMM, started developing mobile phone tech as early as 1989.

Back then, mobile phones were an expensive toy for the ultra-rich…

The Motorola MicroTAC cost a tear-jerking $9,900…

But today, you can get a mobile phone that’s thousands of times more powerful, and for a tiny fraction of the cost…

In fact, there are now almost as many mobile phone subscriptions (6.8 billion) as there are people on Earth (7 billion).

And the savvy few who predicted the mobile phone revolution made a stunning fortune…

QUALCOMM went from a tiny startup to a $25 billion behemoth…

And early QUALCOMM investors could have booked a 7,156% gain…

That’s enough to turn $10,000 into $715,600 in a single trade.

Think of all the other companies that have made massive fortunes for themselves and investors because of the mobile phone revolution too…

Apple… Samsung… Intel… … And many more.

I was also an industry executive at the time of the internet boom, as the world was rapidly making the transition from analog to digital.

I was lucky enough to have been selected by my company at the time, General Instrument, to go to Asia and help grow its business in the most dynamic part of the world.

So I saw firsthand how high-speed internet changes people’s lives, and I also saw the incredible fortunes to be made by investing in it…

Take Netflix (NASDAQ: NFLX), for example…

High-speed internet let Netflix launch their online video streaming service in 2007, “disrupting the living room” and changing home entertainment forever…

Shares soared 2,769% since then.

That’s enough to turn $10,000 into $276,900 in a single trade.

But again, it’s not just Netflix… dozens of companies have benefited from high-speed internet and so have their investors…

Amazon… Cisco… Salesforce… And many more!

Point is, I’ve been on the inside for 25 years and seen what it takes to turn fledgling tech trends into a trillion-dollar industries…

And I’ve developed a system for spotting these explosive trends very early, and riding them for huge gains…

For example, here’s a list of some of my past personal winners:

  • 743% in 3 days on Infospace
  • 940% on NXP Semiconductor
  • 236% on Cornerstone Capital
  • 411% on PNC
  • 308% on P. Dome
  • 459% on Mag
  • And 449% on Fronteer

It’s important to note that these aren’t hypothetical…

They’re real-life trades I made…

And here’s how I do it…

STEP ONE

The first thing you should know is that I begin digging into these Venture Elite companies years in advance.

For example, many of the companies I’m investigating today are the businesses that will go public in 2018 and 2019. That’s how far ahead I’m planning.

Nobody else is doing this right now.

Consider Editas Medicine, a company I recently recommended to readers of my Exponential Tech Investor service…

I’d been following the company’s breakthrough technology since 2012.

STEP TWO

In the second step, I carefully monitor a company’s private financing.

When Editas began its SERIES A round of raising capital, four very credible names invested in the company, including:

  • The Partners Innovation Fund—which is backed by Massachusetts General Hospital and Brigham and Women’s Hospital.
  • And Third Rock Ventures, which is one of the biggest names in biotech Venture Capital.

They’ve backed a slew of biotech startups, including Agios and Bluebird Bio, both of which jumped 300%.

STEP THREE

Finally…

The company files its S-1 form, and then follows up with an S-1/A for, which means there’s a high likelihood it’s going public very soon.

By this point, I’ve done all of my due diligence.

I know the company is a buy and I’m just waiting for the precise date it’ll be available on the stock market.

For example, by the time Editas filed its S-1/A, I’d been following it for two and a half years!

So I was very confident in its potential, and was able to recommend my readers buy as soon as it IPO’d.

So that’s it—3 simple, straightforward steps. And all you need to know is that when you get an alert from me…make sure you act on it right away should you decide it’s the right move for you…

Some of these plays may take a couple months to pop.

But others jump right away—and if you drag your feet, you may miss out on a lot of money.

For example, Dicerna Pharmaceuticals stock price shot up 206% in 24 hours.

And Editas, the company I recently recommended to my readers soared as high as 171% in a little over two months.

This is why I’m so excited about the tiny “gene hacking” company I’ve been telling you about…

Because I’ve been following the technology for years now, and I think it could be bigger and more important than anything else in my lifetime, and yours…

It has the power to completely change the world of medicine, and life as we know it…

End disease, substantially increase lifespans, and much more!

A truly major banking crisis

An interesting paragraph I just found in International man ou Doug Casey newsletters. Interesting enough to be shared. It will help you to make sense of it all…

Much worse than that of 2007-2009. Governments, who are all bankrupt, borrow money from commercial banks. Commercial banks have lent it to them because they believe it’s a risk-free loan. Governments encourage them to lend recklessly, hoping that will jump-start sluggish economies. Central banks, which are the arms of their governments, have taken interest rates to zero and below for that reason and to make it easier for governments to service their debt. This policy has encouraged businesses to take on debt.

It’s an idiotic and reckless experiment that will end—likely in this cycle—with bankrupt central banks and governments bailing out bankrupt commercial banks and businesses. Just the way they did in 2007-2009. Except this time, the situation is much more serious.